NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on January 26 the European Medicines Agency (EMA) validated for review a Type II variation application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). If approved, PADCEV with K ...

– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival – – If approved, PADCEV with KEYTRUDA would be the first combination in the EU to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line locally advanced or metastatic urothelial cancer – TOKYO and NEW YORK, Jan. 26, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer In ...

Wall Street analysts expect Pfizer (PFE) to post quarterly loss of $0.19 per share in its upcoming report, which indicates a year-over-year decline of 116.7%. Revenues are expected to be $14.36 billion, down 40.9% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 1.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ahe ...

System1 Group (AIM:SYS1) climbed 23% on Wednesday as the marketing firm said recent deals with the likes of Tesco, Pfizer and M&S meant full-year expectations would be smashed. Some 60 new clients signed with AIM-listed System1 over the third quarter, taking the number to over 200 for the year so far, the company updated on Wednesday. This included the likes of Pfizer, M&S, Tesco, easyJet, Toyota, Muller, B&Q, and Just Eat most recently, with System1 providing tests to assess effectiveness of marketing idea ...

Pfizer (PFE) will report fourth-quarter and full-year 2023 results on Jan 30, before market open. In the last reported quarter, the company beat earnings expectations by 46.88%.Factors to NotePfizer’s revenues are expected to have declined in the fourth quarter of 2023 due to steep declines in revenues from its COVID-19 products on lower demand.Pfizer records direct sales and alliance revenues from its partner, BioNTech, for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill ...

I can sum up Pfizer's (PFE 0.42%) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set in late 2022.Pfizer's revenue and earnings are sinking like a brick. Big hurdles for the company lie ahead. All in all, this big pharma stock might look like one that investors won't want to touch with a 10-foot pole.However, I'm actually bullish about Pfizer over the long term. Here's why it's a much better sto ...

The market expects Pfizer (PFE) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 30, 2024, might help the stock move higher if these key numbers are bett ...

Oscar Wong/Moment via Getty Images Pfizer (NYSE:PFE) stock is an increasingly popular option for dividend growth investors due to its 14-year dividend growth streak, strong balance sheet, 6% yield, and what appears to be a deeply discounted stock price after the stock's brutal sell-off over the past two years: Data by YCharts However, I do not believe that PFE is attractive enough to warrant buying at this point, and in this article, I explain why. The Bull Case For PFE Stock Despite facing a challengi ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned -0.8%, compared to the Zacks S&P 500 composite's +0.9% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Pfizer falls in, has gained 7.1%. The key question now is: What could be the stock's future direction?Although media reports ...

Michael M. Santiago It's one thing to find a cheaply valued company and another thing to identify a lucrative investment opportunity. Pfizer Inc. (PFE) has been cheap for some time now, with the pharmaceutical giant suffering from lackluster growth in the post-pandemic era with the positive financial impact of Comirnaty and Paxlovid waning. Last November, I found Pfizer cheaply valued, but I failed to identify a catalyst that could drive PFE stock higher in the foreseeable future. In my previous article, af ...